--- title: "Nasopharyngeal Carcinoma - Staging, Investigations, Treatment" description: "ENT notes on Nasopharyngeal Carcinoma - Staging, Investigations, Treatment." source: "The ENT Resident" author: "Dr. Mausumi Das" canonical_url: "https://www.theentresident.com/ent-notes-lectures/nasopharyngeal-carcinoma-staging-treatment" categories: ["Pharynx"] video: "https://www.youtube.com/watch?v=-R4G1XNeXOQ" image: "https://media.theentresident.com/og-images/nasopharyngeal-carcinoma-staging-treatment.png" --- # Nasopharyngeal Carcinoma - Staging, Investigations, Treatment ENT notes on Nasopharyngeal Carcinoma - Staging, Investigations, Treatment. Watch the full video lecture on YouTube: https://www.youtube.com/watch?v=-R4G1XNeXOQ ## 🎗️ Nasopharyngeal Carcinoma - Staging, Investigations & Management ### 🔍 Investigations of Nasopharyngeal Carcinoma Primary goals: - **Visualize and localize** the lesion (endoscopy ± biopsy) - **Stage** extent of local, nodal and distant disease (imaging) - **Baseline assessments** for treatment planning and toxicity monitoring 🧭 **1- Endoscopic evaluation & biopsy** - **Nasal endoscopy / posterior rhinoscopy** - inspect nasopharynx, note site (fossa of Rosenmüller common), growth type and lateral/parapharyngeal extension. >Describe the endoscopic appearance of mass in Nasopharyngeal Carcinoma. - **Biopsy = Gold standard** for diagnosis. >Where should the biopsy be taken from in case of occult neck metastasis? 🔊 **2- Baseline Audiogram** - Detect **serous otitis media / conductive loss** at presentation. - Essential before chemoradiation to monitor for **ototoxicity** and radiation-related SNHL. 🖥️ **3- Imaging** - **Contrast-enhanced CT (CECT) neck & nasopharynx** - Good for initial mapping: primary, parapharyngeal extension, skull-base bone involvement, nodal disease. - Useful for surgical/neck planning. - **MRI (preferred for local staging & planning)** - **Best for soft-tissue delineation** (parapharyngeal space, perineural spread, marrow infiltration). - Superior for assessing **skull base, cavernous sinus, optic apparatus** and for post-treatment surveillance. - **Ultrasound (neck)** - Evaluate cervical nodes. - **USG guided FNAC** increases cytology accuracy. Operator-dependent; not fused with cross-sectional imaging. - **18-FDG PET/CT** - Useful to detect **distant metastasis**, assess metabolic extent of loco-regional disease and detect residual / recurrent disease. - Consider PET when staging advanced disease or investigating suspected recurrence. - **Bone scan / CT chest / CT abdomen** or **CT thorax + liver imaging** - For suspected bony, pulmonary or hepatic metastases. 🧪 **4-Lab & molecular markers** - **FNAC of nodes** — cytologic confirmation of metastatic disease. - **EBV-related tests**: - **Serology**: IgA to Viral Capsid Antigen (VCA) - sensitive (screening) and IgA to Early Antigen - more specific. - **Plasma EBV DNA (quantitative)** - highly useful: diagnostic adjunct, prognostic marker, and **dynamic marker for treatment response / surveillance**. - High pre-treatment EBV DNA → correlates with greater tumor burden/advanced stage. - Rapid fall to undetectable post-treatment → good response. Persistent or rising levels → persistent disease / recurrence. - **Nasopharyngeal brushing** for EBV DNA — high sensitivity/specificity; can outperform plasma in some settings. --- ### 🧾 Staging (AJCC) of Nasopharyngeal Carcinoma - **T (tumor):** - **T1:** Tumour confined to nasopharynx, or extends to oropharynx and/or nasal cavity without parapharyngeal involvement - **T2:** Tumour with extension to parapharyngeal space and/or infiltration of the medial pterygoid, lateral pterygoid and/or prevertebral muscles. - **T3:** Tumour invades bony structures of skull base cervical vertebra, pterygoid structures and/or paranasal sinuses - **T4:** Tumour with intracranial extension and/or involvement of cranial nerves, hypopharynx, orbit, parotid gland and/or infiltration beyond the lateral surface of the lateral pterygoid muscle - **N (nodes):** - **Nx:** Regional lymph nodes cannot be assessed - **N0:** No regional lymph node metastasis - **N1:** Unilateral metastasis, in cervical lymph node(s), and/or unilateral or bilateral metastasis in retropharyngeal lymph nodes, 6 cm or less in greatest dimension, above the caudal border of cricoid cartilage - **N2:** Bilateral metastasis in cervical lymph node(s), 6 cm or less in greatest dimension, above the caudal border of cricoid cartilage - **N3:** Metastasis in cervical lymph node(s) greater than 6 cm in dimension and/or extension below the caudal border of cricoid cartilage - **M (metastasis):** - **M0:** no distant mets - **M1:** distant metastasis. --- ### 🧩 Differential diagnosis of Nasopharyngeal Carcinoma - **Inflammatory:** chronic rhinosinusitis, nasal polyposis. - **Infective:** nasopharyngeal TB, fungal. - **Other neoplasms:** NK/T-cell lymphoma, mucosal melanoma, sinonasal undifferentiated carcinoma, olfactory neuroblastoma, other rare sarcomas. --- ### 🎯 Treatment of Nasopharyngeal Carcinoma - **Nasopharyngeal Carcinoma is highly radiosensitive** (especially non-keratinizing/undifferentiated types). **Radiotherapy** is the cornerstone for most stages (I–IVA/B). - **Surgery is NOT first line** for primary Nasopharyngeal Carcinoma (anatomic inaccessibility and excellent radiocurability). **PLAN:** - **Stage I (and selected low-risk stage II):** **radical radiotherapy alone**. - **Stage II (high tumor load), Stage III–IVA/B:** **concurrent chemoradiotherapy (CCRT)** ± adjuvant chemotherapy. - **Stage IVC (M1):** systemic therapy ± local ablative options for oligometastasis. **🧮 Radiotherapy details** - **Technique:** Intensity-modulated radiotherapy (**IMRT**) is standard — spares normal structures and improves local control & toxicity profile. - **Dose examples:** GTV → ~70 Gy; CTV2 → ~60 Gy (institutional protocols vary). >What is Gross Target volume? >What is Clinical Target volume? >What is Planning Target volume? **💊 Chemotherapy** - **Concurrent cisplatin** (weekly 30–40 mg/m² or 3-weekly 100 mg/m²) during RT is common for locally advanced disease. - **Adjuvant cisplatin + 5-FU** (historically used) or other regimens may follow in high-risk patients. - **Metastatic / recurrent disease:** platinum-based doublets (cisplatin + 5-FU). Newer agents (gemcitabine, taxanes, capecitabine, immune therapies) used in selected settings/trials. - **Total cumulative cisplatin dose** of ≥200 mg/m² often targeted to confer survival benefit. --- ### 🔁 Salvage treatment (persistent / recurrent disease) **1- Local (nasopharyngeal) failure** - **Re-irradiation** options: stereotactic RT, IMRT re-irradiation, or brachytherapy for small lesions (Ir-192, Au-198) — suitable for lesions ≤2 cm. - **Surgical salvage (nasopharyngectomy):** reserved for selected resectable recurrences and where re-irradiation contraindicated. Multiple approaches exist; surgery is technically demanding and morbid: - Transpalatal approach - Trans-cervico-mandibulo-palatal approach - Midfacial degloving approach - Maxillary swing approach - Facial translocation / lateral skull base approaches - Endoscopic / transnasal / transoral and robotic approaches **2- Nodal failure** - **Persistent large nodes at 3 months post RT** → consider salvage therapy. - **Options:** surgical neck dissection ± brachytherapy / re-irradiation. - **Surgery often required:** **radical neck dissection** (high extracapsular spread rates in NPC). - **If vital structures invaded (carotid, brachial plexus):** often palliative approach; avoid radical resection of vital structures. --- ### 🌍 Treatment of Metastatic disease - **Oligometastatic disease** (single/limited mets): consider **surgical resection**, **radiofrequency ablation**, or **stereotactic radiotherapy** (ablative local therapy). - **Systemic therapy** for metastatic / disseminated disease - **cisplatin + 5-FU** first-line; gemcitabine, taxanes, capecitabine as second line. --- ### 🔁 Post-treatment surveillance & follow-up of Nasopharyngeal Carcinoma - **Clinical surveillance:** frequent early review: - **Years 0–2:** every **2–3 months**. - **Years 3–5:** every **3–4 months** (or 3–4×/year). - **After 5 years:** **6-monthly to yearly** reviews. - **Endoscopic evaluation** at follow-ups; **biopsy only ≥10–12 weeks post-RT** if residual suspicious tissue. - **Imaging (MRI / PET)** as indicated for suspected residual / recurrent disease. - **Serial plasma EBV DNA** useful for earlier detection of recurrence (rising levels prompt targeted evaluation). - **Audiometry** and other organ-specific monitoring for late toxicities. --- ### 📈 Prognosis of Nasopharyngeal Carcinoma - **Overall good for early-stage disease** with modern IMRT ± chemo. - **5-year disease-specific survival (illustrative):** - **Stage I:** ~100% - **Stage II:** ~90% - **Stage III / IVA:** ~67% - **Stage IVB:** ~68% (depends on nodal/extensive local disease) - **Stage IVC (distant mets):** ~18% - **Best outcomes** seen in **non-keratinizing / undifferentiated (lymphoepithelioma)** — strongly EBV-associated and highly radiosensitive. - **IMRT + concurrent chemo** has markedly improved loco-regional control and survival. --- ## About This Note This free ENT note on Nasopharyngeal Carcinoma - Staging, Investigations, Treatment was written by Dr. Mausumi Das and is paired with a corresponding video lecture. Canonical page of this note: https://www.theentresident.com/ent-notes-lectures/nasopharyngeal-carcinoma-staging-treatment When citing or referencing this content, please credit The ENT Resident and link to the canonical page above. ## Related Notes by Category - Pharynx: https://www.theentresident.com/ent-notes-lectures/category/pharynx.md ## About The ENT Resident The ENT Resident is an educational website and resource library created by Dr. Mausumi Das (MS ENT) for ENT residents, ENT postgraduates preparing for exams, and MBBS students. Dr. Mausumi Das writes the notes, draws the diagrams, and records the lectures herself. Browse all ENT notes and lectures on The ENT Resident: https://www.theentresident.com/ent-notes-lectures.md ## Medical-use Boundary The ENT Resident provides educational material for medical learning and revision. It does not provide patient-specific medical advice, diagnosis, or emergency care, and it is not a substitute for evaluation by a qualified healthcare professional. ## More Resources - Learn about the Premium ENT Notes, preview a complete sample, and find purchase options: https://www.theentresident.com/premium.md - Premium note for this topic, Nasopharyngeal Carcinoma - Staging, Investigations, Treatment: https://theentresident.gumroad.com/l/mjgqep - Read student testimonials: https://www.theentresident.com/testimonials.md - Contact The ENT Resident: https://www.theentresident.com/contact.md --- A complete index of all pages on this site, with descriptions and markdown links can be found here: https://www.theentresident.com/llms.txt